產(chǎn)品詳情
簡單介紹：
Anti-SNF2L抗體產(chǎn)品質量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-SNF2L抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-SNF2L
Cat. Number:
Anti-SNF2L抗體KL-6015R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SNF2L, also known as SMARCA1 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1), SWI or ISWI, is a 1,054 amino acid protein that localizes to the nucleus and contains one Anti-SNF2L抗體helicase C-terminal domain, one helicase ATP-binding domain and two SANT domains. Expressed as multiple alternatively spliced isoforms, SNF2L exists as a component of the nucleosome-remodeling factor (NURF) complex where it helps to facilitate the ATP-dependent perturbation of chromatin structure and may also be involved in brain development and neurite outgrowth. The gene encoding SNF2L maps to human chromosome X, which contains nearly 153 million base pairs and houses over 1,000 genes.
Also known as:
global transcription activator Anti-SNF2L抗體homologous sequence; SMARCA1; SNF2-like 1; SNF2L; SNF2L1; SNF2LB; sucrose nonfermenting 2-like protein 1; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 1; SWI2; SMCA1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Anti-SNF2L抗體Rat, Chicken, Pig, Cow, Horse, Rabbit, .
●
Immunogen: KLH conjugated synthetic peptide derived from human SMARCA1.
●
Predicted Molecular Weight: 116kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SNF2L抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-SNF2L抗體
Optimal working dilutions must be determined by the end user.
